Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

書誌詳細
主要な著者:	Jadersten, M, Pellagatti, A, Forsblom, A, Emanuelsson, E, Merup, M, Samuelsson, J, Wainscoat, J, Boultwood, J, Hellstorm-Lindberg, E
フォーマット:	Conference item
出版事項:	2005

類似資料

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
著者:: Pellagatti, A, 等
出版事項: (2006)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
著者:: Pellagatti, A, 等
出版事項: (2007)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
著者:: Jädersten, M, 等
出版事項: (2009)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
著者:: Scharenberg, C, 等
出版事項: (2011)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
著者:: Martin Jädersten, 等
出版事項: (2009-12-01)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
著者:: Pellagatti, A, 等
出版事項: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
著者:: Pellagatti, A, 等
出版事項: (2011)

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion
著者:: Martin Jädersten
出版事項: (2010-03-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
著者:: Nikpour, M, 等
出版事項: (2007)

Gene expression profiling in the myelodysplastic syndromes.
著者:: Pellagatti, A, 等
出版事項: (2005)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
著者:: Raza Azra, 等
出版事項: (2012-04-01)

Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
著者:: Lewis, S, 等
出版事項: (1995)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
著者:: Pellagatti, A, 等
出版事項: (2009)

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
著者:: Maria Ximeri, 等
出版事項: (2010-03-01)

The impact of spliceosome mutations in MDS
著者:: Jacqueline Boultwood, 等
出版事項: (2019-06-01)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
著者:: Pellagatti, A, 等
出版事項: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
著者:: Pellagatti, A, 等
出版事項: (2010)

5q- syndrome.
著者:: Boultwood, J, 等
出版事項: (2012)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
著者:: Pellagatti, A, 等
出版事項: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
著者:: Pellagatti, A, 等
出版事項: (2010)

Clonality in the myelodysplastic syndromes.
著者:: Boultwood, J, 等
出版事項: (2001)

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
著者:: Caceres, G, 等
出版事項: (2013)

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
著者:: Gudrun Göhring, 等
出版事項: (2011-02-01)

The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
著者:: Nilsson, L, 等
出版事項: (2007)

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
著者:: Axel Rüfer, 等
出版事項: (2022-07-01)

Molecular pathogenesis of the myelodysplastic syndromes
著者:: Boultwood, J, 等
出版事項: (1999)

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide
著者:: Virginie Eclache, 等
出版事項: (2008-02-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
著者:: Pellagatti, A, 等
出版事項: (2003)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
著者:: Pellagatti, A, 等
出版事項: (2009)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
著者:: Botezatu, L, 等
出版事項: (2016)

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide
著者:: Bagi Jana, 等
出版事項: (2014-01-01)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
著者:: Pellagatti, A, 等
出版事項: (2005)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
著者:: Boultwood, J, 等
出版事項: (2012)

Telomere length in myelodysplastic syndromes.
著者:: Boultwood, J, 等
出版事項: (1995)

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
著者:: Pellagati, A, 等
出版事項: (2008)

Advances in the 5q- syndrome.
著者:: Boultwood, J, 等
出版事項: (2010)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
著者:: Pellagatti, A, 等
出版事項: (2004)

The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells
著者:: Brigitte Mohr, 等
出版事項: (2009-03-01)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
著者:: Yu Han Koh, 等
出版事項: (2023-08-01)

PP2A: The Achilles Heal in MDS with 5q Deletion
著者:: David eSallman, 等
出版事項: (2014-09-01)